159 related articles for article (PubMed ID: 29956845)
1. Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?
Greenbaum U; Joffe E; Filanovsky K; Oster HS; Kirgner I; Levi I; Raanani P; Avivi I; Manor E; Man-El G; Mittelman M
Eur J Haematol; 2018 Oct; 101(4):502-507. PubMed ID: 29956845
[TBL] [Abstract][Full Text] [Related]
2. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
Wang H; Wang XQ; Xu XP; Lin GW
Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
5. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.
Schemenau J; Baldus S; Anlauf M; Reinecke P; Braunstein S; Blum S; Nachtkamp K; Neukirchen J; Strup C; Aul C; Haas R; Gattermann N; Germing U
Eur J Haematol; 2015 Sep; 95(3):181-9. PubMed ID: 25600827
[TBL] [Abstract][Full Text] [Related]
6. Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes.
Wu A; Gao P; Wu N; Shi C; Huang Z; Rong C; Sun Y; Sheng L; Ouyang G; Mu Q
BMC Cancer; 2021 May; 21(1):546. PubMed ID: 33985456
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes.
Molteni A; Riva M; Cesana C; Speziale V; Nichelatti M; Scarpati B; Greco R; Ravano E; Cairoli R; Rossini S; Morra E
Eur J Haematol; 2015 Jun; 94(6):519-25. PubMed ID: 25307971
[TBL] [Abstract][Full Text] [Related]
8. Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.
Neukirchen-Strapatsas J; Tuechler H; Porta MD; Fenaux P; Guerci A; Haas R; Rossi M; Sapena R; Sperr WR; Strupp C; Stamatoullas A; Valent P; Germing U; Bennett JM
Leuk Res; 2019 Feb; 77():8-13. PubMed ID: 30605856
[TBL] [Abstract][Full Text] [Related]
9. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies.
Huang TC; Ko BS; Tang JL; Hsu C; Chen CY; Tsay W; Huang SY; Yao M; Chen YC; Shen MC; Wang CH; Tien HF
Leukemia; 2008 Mar; 22(3):544-50. PubMed ID: 18094713
[TBL] [Abstract][Full Text] [Related]
10. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
11. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
12. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
13. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
Xiong B; Nie Y; Tang Z; Xue M; Zuo X
Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
[TBL] [Abstract][Full Text] [Related]
14. Hypocellular myelodysplastic syndromes (MDS): new proposals.
Tuzuner N; Cox C; Rowe JM; Watrous D; Bennett JM
Br J Haematol; 1995 Nov; 91(3):612-7. PubMed ID: 8555063
[TBL] [Abstract][Full Text] [Related]
15. Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
Mashima K; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Ashizawa M; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 May; 98(5):1127-1133. PubMed ID: 30474718
[TBL] [Abstract][Full Text] [Related]
16. Revised international prognostic scoring system for myelodysplastic syndromes.
Greenberg PL; Tuechler H; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Malcovati L; Cazzola M; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres M; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D
Blood; 2012 Sep; 120(12):2454-65. PubMed ID: 22740453
[TBL] [Abstract][Full Text] [Related]
17. Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).
Bennett JM; Tuechler H; Aul C; Strupp C; Germing U
Leuk Res; 2016 Aug; 47():63-9. PubMed ID: 27258735
[TBL] [Abstract][Full Text] [Related]
18. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.
Ramos F; Robledo C; Izquierdo-García FM; Suárez-Vilela D; Benito R; Fuertes M; Insunza A; Barragán E; Del Rey M; García-Ruiz de Morales JM; Tormo M; Salido E; Zamora L; Pedro C; Sánchez-Del-Real J; Díez-Campelo M; Del Cañizo C; Sanz GF; Hernández-Rivas JM;
Oncotarget; 2016 May; 7(21):30492-503. PubMed ID: 27127180
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors.
Ríos A; Cañizo MC; Sanz MA; Vallespí T; Sanz G; Torrabadella M; Gomis F; Ruiz C; San Miguel JF
Br J Haematol; 1990 May; 75(1):26-33. PubMed ID: 2375920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
